Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
N Engl J Med 2021;385:2252–63 doi: 10.1056/NEJMoa2110956
This double-blind, placebo-controlled, event-driven Phase 3 trial by Pitt et al. randomised 7,437 patients to finerenone and placebo, as well as treatment with a renin-angiotensin blockade.